Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal Health to offer MicroPhage's one-day antibiotic-resistance test to NA customers

This article was originally published in Clinica

Executive Summary

Privately-held MicroPhage is to see its first product, an antibiotic susceptibility and resistance test, distributed to hospitals and healthcare centres across North America, after striking a deal with multi-billion-dollar healthcare products and services provider Cardinal Health. The latter will be the exclusive distributor of the recently FDA-cleared KeyPath MRSA/MSSA blood culture test – BT, which provides same-day results to confirm the presence of Staphylococcus aureus and identify whether the bacteria is either methicillin-resistant or –susceptible. Additionally, under the agreement, Cardinal Health will have exclusive rights to other products in Longmont, Colorado-based MicroPhage's pipeline which test blood culture specimens for S aureus. In exchange for these rights, Cardinal will invest in Cardinal for an undisclosed amount to help fund the development and commercialisation of these new products.

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

UsernamePublicRestriction

Register

MT098009

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel